Journal of Gastroenterology

, Volume 44, Issue 7, pp 666–674 | Cite as

Unbalanced expression of protease-activated receptors-1 and -2 in the colon of diarrhea-predominant irritable bowel syndrome patients

  • Zhao Xiang Bian
  • Zhi Li
  • Zhi Xin Huang
  • Man Zhang
  • Hong Li Chen
  • Hong Xi Xu
  • Joseph J. Y. Sung
Original Article—Alimentary Tract



The aim of this study is to determine whether a changed expression ratio of PAR-1 and PAR-2 in the colon is associated with diarrhea-predominant IBS patients.


PAR-1, -2, thrombin, mast cell tryptase, tryptophan hydroxylase (TPH), and chromgranin A (ChrA) in colonic biopsy samples from 10 diarrhea-predominant IBS patients and 13 healthy control subjects were semiquantified with immunofluorescence and image analysis. Serotonin concentrations in biopsy samples were evaluated by capillary electrophoresis.


Significantly lower expression of PAR-1 and higher expression of mast cell tryptase was detected in the colons of patients, with statistically unchanged expression of PAR-2. Thrombin-, TPH-, and ChrA-positive cells were markedly increased in IBS patients, but no significant difference in serotonin concentration existed in the colons between two groups. The ratio of PAR-1/PAR-2 expression was significantly decreased in patients (0.33 ± 0.19 versus 0.66 ± 0.22, P = 0.001) and negatively correlated to ChrA-positive cells.


Changed expression ratio of PAR-1 to PAR-2 in the colon is connected with diarrhea-predominant IBS patients. Methods to restore an appropriate balance of PAR-1 and PAR-2 activation in the colon may offer a promising future therapeutic strategy for IBS patients.


Irritable bowel syndrome (IBS) Protease-activated receptors (PARs) Serotonin (5-HT) 



This study was supported by grants from the Jockey Club Institute of Chinese Medicine, Hong Kong (JCICM-16-02), and Hong Kong Baptist University Faculty research Grant (FRG/06-07/II-72).


  1. 1.
    Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut. 2000;46:78–82.PubMedCrossRefGoogle Scholar
  2. 2.
    Foxx-Orenstein A. IBS—review and what’s new. Med Gen Med. 2006;8:20.Google Scholar
  3. 3.
    Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360:555–64.PubMedCrossRefGoogle Scholar
  4. 4.
    Schwetz I, Bradesi S, Mayer EA. The pathophysiology of irritable bowel syndrome. Minerva Med. 2004;95:419–26.PubMedGoogle Scholar
  5. 5.
    Spiller RC. Irritable bowel syndrome. Br Med Bull. 2005;72:15–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Mayer EA, Naliboff BD, Chang L, Coutinho SV. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2001;280:G519–24.PubMedGoogle Scholar
  7. 7.
    Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut. 2001;49:743–5.PubMedCrossRefGoogle Scholar
  8. 8.
    Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci USA. 1999;96:11023–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Vergnolle N. Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol. 2004;141:1264–74.PubMedCrossRefGoogle Scholar
  10. 10.
    Noorbakhsh F, Vergnolle N, Hollenberg MD, Power C. Proteinase-activated receptors in the nervous system. Nat Rev Neurosci. 2003;4:981–90.PubMedCrossRefGoogle Scholar
  11. 11.
    Coelho A, Bunnett NW. Intestinal activation of proteinase-activated receptor-1 (PAR1) reduces visceral nociception associated to rectal distension (RD) in rats. Gastroenterology 2003;124:A-1.Google Scholar
  12. 12.
    Asfaha S, Brussee V, Chapman K, Zochodne DW, Vergnolle N. Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br J Pharmacol. 2002;135:1101–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Vergnolle N, Cellars L, Chapman K. Proteinase-activated receptor-1 agonists attenuate visceral pain. Gastroenterology 2003;124:A-252.Google Scholar
  14. 14.
    Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev. 2002;54:203–17.PubMedCrossRefGoogle Scholar
  15. 15.
    Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, et al. Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med. 2001;7:821–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Reed DE, Barajas-Lopez C, Cottrell G, Velazquez-Rocha S, Dery O, Grady EF, et al. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. J Physiol. 2003;547:531–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest. 2007;117:636–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Li Z, Zhang XJ, Xu HX, Sung JJY, Bian ZX. Intracolonical administration of protease-activated receptor-2 agonists produced visceral hyperalgesia by up-regulating serotonin in the colon of rats. Eur J Pharmacol. 2009;606(1–3):199–204.PubMedCrossRefGoogle Scholar
  19. 19.
    Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397–414.PubMedCrossRefGoogle Scholar
  20. 20.
    Grundy D. Serotonin and sensory signalling from the gastrointestinal lumen. J Physiol. 2006;575(Pt 1):1–2.PubMedCrossRefGoogle Scholar
  21. 21.
    Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 2004;141:1285–93.PubMedCrossRefGoogle Scholar
  22. 22.
    Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 2000;47:804–11.PubMedCrossRefGoogle Scholar
  23. 23.
    Crowell MD, Shetzline MA, Moses PL, Mawe GM, Talley NJ. Enterochromaffin cells and 5-HT signaling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs. 2004;5:55–60.PubMedGoogle Scholar
  24. 24.
    Mawe GM, Coates MD, Moses PL. Review article: intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther. 2006;23:1067–76.PubMedCrossRefGoogle Scholar
  25. 25.
    Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion. 2001;63:188–94.PubMedCrossRefGoogle Scholar
  26. 26.
    Drossman DA, Corrazziari E, Delvaux M, Spiller RC, Talley NJ, Thompson WG, et al. Rome III: the functional gastrointestinal disorders diagnosis, pathophysiology, and treatment: a multinational consensus. Mclean, VA: Degnon Association; 2006.Google Scholar
  27. 27.
    Sjolund K, Sanden G, Hakanson R, Sundler F. Endocrine cells in human intestine: an immunocytochemical study. Gastroenterology. 1983;85:1120–30.PubMedGoogle Scholar
  28. 28.
    Du M, Flanigan V, Ma Y. Simultaneous determination of polyamines and catecholamines in PC-12 tumor cell extracts by capillary electrophoresis with laser-induced fluorescence detection. Electrophoresis. 2004;25:1496–502.PubMedCrossRefGoogle Scholar
  29. 29.
    Kawao N, Ikeda H, Kitano T, Kuroda R, Sekiquchi F, Kataoka K, et al. Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J Pharmacol Sci. 2004;94:277–85.PubMedCrossRefGoogle Scholar
  30. 30.
    Coelho AM, Vergnolle N, Guiard B, Fioramonti J, Bueno L. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology. 2002;122:1035–47.PubMedCrossRefGoogle Scholar
  31. 31.
    Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRefGoogle Scholar
  32. 32.
    Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol. 2006;21:71–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Kawabata A, Kawao N, Kuroda R, Tanaka A, Shimada C. The PAR-1-activating peptide attenuates carrageenan-induced hyperalgesia in rats. Peptides. 2002;23:1181–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Fang M, Kovacs KJ, Fisher LL, Larson AA. Thrombin inhibits NMDA-mediated nociceptive activity in the mouse: possible mediation by endothelin. J Physiol. 2003;549:903–17.PubMedCrossRefGoogle Scholar
  35. 35.
    Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol. 2005;36:676–85.PubMedCrossRefGoogle Scholar
  36. 36.
    MacNaughton WK. Epithelial effects of proteinase-activated receptors in the gastrointestinal tract. Mem Inst Oswaldo Cruz. 2005;100(Suppl 1):211–5.PubMedGoogle Scholar

Copyright information

© Springer 2009

Authors and Affiliations

  • Zhao Xiang Bian
    • 1
  • Zhi Li
    • 1
  • Zhi Xin Huang
    • 2
  • Man Zhang
    • 1
  • Hong Li Chen
    • 1
  • Hong Xi Xu
    • 3
  • Joseph J. Y. Sung
    • 4
  1. 1.School of Chinese MedicineHong Kong Baptist UniversityKowloon Tong, Hong Kong SARChina
  2. 2.Guangzhou University of Traditional Chinese MedicineGuangzhouPeoples Republic of China
  3. 3.Hong Kong Jockey Club Institute of Chinese MedicineHong Kong SARChina
  4. 4.Faculty of MedicineThe Chinese University of Hong KongHong Kong SARChina

Personalised recommendations